148 related articles for article (PubMed ID: 10516752)
21. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
22. Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation.
Okoshi Y; Shimizu S; Kojima H; Obara N; Mukai HY; Komeno T; Hasegawa Y; Mori N; Nagasawa T
Acta Haematol; 2001; 105(1):45-8. PubMed ID: 11340253
[TBL] [Abstract][Full Text] [Related]
23. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission.
Diverio D; Pandolfi PP; Biondi A; Avvisati G; Petti MC; Mandelli F; Pelicci G; Lo Coco F
Blood; 1993 Dec; 82(12):3556-9. PubMed ID: 8260693
[TBL] [Abstract][Full Text] [Related]
24. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements].
Gong XY; Wang Y; Liu BC; Wei H; Li CW; Li QH; Zhao JW; Zhou CL; Lin D; Liu KQ; Wei SN; Gong BF; Zhang GJ; Liu YT; Zhao XL; Li Y; Gu RX; Qiu SW; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):9-14. PubMed ID: 29551026
[No Abstract] [Full Text] [Related]
26. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
Matsuo H; Iijima-Yamashita Y; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):41-46. PubMed ID: 29067751
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.
Sarashina T; Iwabuchi H; Miyagawa N; Sekimizu M; Yokosuka T; Fukuda K; Hamanoue S; Iwasaki F; Goto S; Shiomi M; Imai C; Goto H
Int J Hematol; 2016 Jul; 104(1):139-43. PubMed ID: 27084248
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
[TBL] [Abstract][Full Text] [Related]
29. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
Archimbaud E; Charrin C; Magaud JP; Campos L; Thomas X; Fière D; Rimokh R
Leukemia; 1998 Jan; 12(1):25-33. PubMed ID: 9436917
[TBL] [Abstract][Full Text] [Related]
30. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia.
Cimino G; Elia L; Rapanotti MC; Sprovieri T; Mancini M; Cuneo A; Mecucci C; Fioritoni G; Carotenuto M; Morra E; Liso V; Annino L; Saglio G; De Rossi G; Foà R; Mandelli F
Blood; 2000 Jan; 95(1):96-101. PubMed ID: 10607691
[TBL] [Abstract][Full Text] [Related]
31. Analysis of acute leukemias with MLL/ENL fusion transcripts: identification of two novel breakpoints in ENL.
Fu JF; Liang DC; Shih LY
Am J Clin Pathol; 2007 Jan; 127(1):24-30. PubMed ID: 17145626
[TBL] [Abstract][Full Text] [Related]
32. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
Langer T; Metzler M; Reinhardt D; Viehmann S; Borkhardt A; Reichel M; Stanulla M; Schrappe M; Creutzig U; Ritter J; Leis T; Jacobs U; Harbott J; Beck JD; Rascher W; Repp R
Genes Chromosomes Cancer; 2003 Apr; 36(4):393-401. PubMed ID: 12619163
[TBL] [Abstract][Full Text] [Related]
33. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
Buonamici S; Ottaviani E; Testoni N; Montefusco V; Visani G; Bonifazi F; Amabile M; Terragna C; Ruggeri D; Piccaluga PP; Isidori A; Malagola M; Baccarani M; Tura S; Martinelli G
Blood; 2002 Jan; 99(2):443-9. PubMed ID: 11781223
[TBL] [Abstract][Full Text] [Related]
34. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
35. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
36. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
[TBL] [Abstract][Full Text] [Related]
37. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes.
Barragán E; Bolufer P; Moreno I; Martín G; Nomdedeu J; Brunet S; Fernández P; Rivas C; Sanz MA
Leuk Lymphoma; 2001 Aug; 42(4):747-56. PubMed ID: 11697505
[TBL] [Abstract][Full Text] [Related]
38. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
39. [Disappearance of residual disease confirmed by RT-PCR following induction chemotherapy in two hypoplastic leukemia patients with t(8;21)].
Sawada M; Tsurumi H; Yamada T; Hara T; Oyama M; Moriwaki H
Rinsho Ketsueki; 1999 Apr; 40(4):311-7. PubMed ID: 10355140
[TBL] [Abstract][Full Text] [Related]
40. Impact of MLL::AF9 Gene Rearrangement on Survival of Acute Myeloid Leukaemia Patients: An Insight into Pakistani Population.
Tariq M; Shahab S; Saeed JR; Hussain Z; Zaidi U; Farzana T; Ahmad S
J Coll Physicians Surg Pak; 2024 Apr; 34(4):424-428. PubMed ID: 38576284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
